Patient appointments
The choice is more useful when it starts with your diagnosis and daily life. ICOTYDE is a daily oral IL-23 receptor antagonist; TREMFYA is an injectable IL-23-blocking antibody. They are different products, with different approved uses and practical requirements.
An appointment does not confirm access to a particular medicine, procedure or specialist. Ask the team about the care and coverage you need.
Medical information checked against current US sources: October 19, 2026.
ICOTYDE is approved for qualifying moderate-to-severe plaque psoriasis from age 12 and at least 40 kg. TREMFYA covers qualifying plaque psoriasis and active psoriatic arthritis from age six and at least 40 kg, as well as moderately to severely active Crohn’s disease or ulcerative colitis in adults.
If your current injection also treats joint or bowel disease, changing to a psoriasis-only pill requires a plan for those conditions. Report morning stiffness, swollen fingers or toes, persistent diarrhea, rectal bleeding and prior IBD diagnoses before selecting treatment.
ICOTYDE is taken as 200 mg each morning on an empty stomach with water, waiting at least 30 minutes before food. TREMFYA’s psoriasis regimen is 100 mg under the skin at weeks 0 and 4, then every eight weeks. Adult injections require training; pediatric self-injection is not recommended.
Needle avoidance, travel, refrigeration, daily adherence, swallowing and breakfast routines can all matter. Discuss what is realistically manageable, rather than choosing only by the number of doses. A treatment that sounds convenient still has to fit the medical indication and safety history.
Both medicines require review of infections and vaccination plans. ICOTYDE calls for consideration of TB evaluation based on clinical judgment and monitoring considerations with reduced kidney function. TREMFYA requires TB evaluation and has indication-specific liver-monitoring requirements.
Neither an oral route nor a lack of a boxed warning proves that a drug is safer for you. Pregnancy, breastfeeding, liver or kidney disease, prior infections and other immune-active medicines should be part of the decision.
The current labels do not provide a direct ICOTYDE-versus-TREMFYA trial. ICOTYDE’s active-comparator trials used deucravacitinib. TREMFYA’s psoriasis program used different comparators and designs. Percent-clear-skin figures from separate studies should not be turned into a head-to-head winner.
Ask what outcome matters most, when it will be reviewed, and what the next step would be if benefit is insufficient. Verify cost and continuation for the specific prescription, including authorization, pharmacy and administration. The least expensive advertised copay is not necessarily your actual total.
No. They affect the IL-23 pathway differently and are separate medicines. ICOTYDE blocks the IL-23 receptor and is an oral peptide; guselkumab is an injectable monoclonal antibody targeting IL-23. Their doses, routes, approved indications and monitoring requirements are not interchangeable.
There is no universal answer and the current labels do not establish a direct head-to-head comparison. The clinician should consider the disease, affected sites, previous response, other diagnoses, safety, administration preference and reliable access. A trial result or a patient story cannot choose for an individual.
Do not combine them unless the treating specialist has explicitly prescribed and reviewed that plan. Do not use a comparison page as permission to overlap immune-active medicines. Bring all prescriptions and the last dose of any current systemic treatment to the review.
The prescriber must decide the transition based on the last dose, reason for switching, infection status and other diagnoses. There is no single safe online schedule for everyone. Confirm the new prescription, pharmacy supply, authorization and follow-up before changing the existing plan.
Tell both treating teams. TREMFYA has an adult Crohn’s indication with a different regimen from psoriasis. ICOTYDE’s current US approval does not include Crohn’s disease. An oral preference alone should not lead to replacing treatment for bowel disease with a psoriasis-only medicine.
Choose a service and clinic in the Nao booking app. Confirm appointment availability and the care you need with the team.